- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03784131
Tissue Engineered Veins in Patients With Chronic Venous Insufficiency (TECVI-1)
Phase I Open-label, First-in-human Study to Evaluate Feasibility and Safety of Tissue Engineered Veins in Patients With Chronic Venous Insufficiency
Study Overview
Detailed Description
The advanced therapy medicinal product (ATMP) described herein is a personalized tissue- engineered vein (P-TEV) graft for use in surgical implantation to replace a defective or missing part of a patient's vein.
In this specific application a P-TEV graft with a functioning venous bicuspid valve is implanted to replace a nonfunctioning venous valve in the femoral vein of a patient suffering from severe CVI. The P-TEV graft for surgical implantation is 4-6 cm in length.
The P-TEV drug substance consists of an extracellular matrix (ECM) scaffold in the form of a decellularized (DC) allogeneic vein scaffold which is populated with autologous components from the patient's own peripheral whole blood (PWB) in an ATMP manufacturing process performed under GMP. As the allogeneic immunogenic material has been removed from the donated vein segment by DC and as the perfusion uses autologous PWB, no immunosuppression is required.
Successful implantation and treatment should prevent the reverse blood flow, decrease blood pooling in the lower leg, and thereby alleviate symptoms such as swelling, pain, and ulcers.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Björquist
- Phone Number: +46705979296 +46705979296
- Email: info@verigraft.com
Study Locations
-
-
-
Sevilla, Spain
- Recruiting
- Junta de Andalusia
-
Contact:
- Petter Björquist, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged between 18 and 75 years (inclusive)
- CVI patients with painful swelling and/or skin changes and/or recurrent leg ulcer despite optimal conservative treatment for a period of time according to the investigator's judgement
- Patients with deep venous reflux (grade 3 and above)
- Meeting ASA (American Society of Anesthesiologists Classification) class 1 or 2 according to the PIs criteria
Laboratory values
- INR <1.7 (in case the patient uses Warfarin, the test might be repeated after the anticoagulant change)
- Platelets ≥ 100 x 10 9 /L
- Hemoglobin ≥ 100 g/L
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- ASAT ≤ 2.5 × ULN
- ALAT ≤ 2.5 × ULN
- Ability to understand the requirements of the study, give direct or representative written informed consent, and comply with the study procedures
Exclusion Criteria:
- Patients incapable to give direct or representative written informed consent
- Patients unlikely to cooperate fully in the study and/or with an anticipated poor compliance
- Non-walking patients or patients with lost ankle joint function
- Patients previously organ-transplanted
- Patients with cancer except in-situ stage cancer (basal-cell carcinomas and/or cervix cancer) and five year recurrence free period after treatment
- Patients with autoimmune diseases including rheumatoid arthritis, SLE and MS
- Pregnant or breast feeding women
- Patients with ongoing estrogen treatment for example for contraception. Alternative contraceptive methods (e.g. intrauterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence) should be used by women of reproductive age (defined as pre-menopausal female capable of becoming pregnant).
- BMI ≥ 35
- Patients who have participated in other clinical trials during the last 12 months
- Patients with artery pathology (ankle-brachial pressure index < 0,9 or > 1,3)
- Patients with thrombophilia according to the laboratory results at inclusion visit. One of the following criteria is needed for thrombophilia: Protein C < 40% or Protein S < 40 % or Leiden factor mutation or Antithrombin III < 40 % or present Lupus anticoagulant or Homocysteine > 1.5 ULN
- Patients with an active infection requiring systemic antibiotic treatment
- Patients with clinically significant cardiac disease (New York Heart Association, Class III or IV) or measured LVEF 40%
- Patients with uncontrolled hypertension
- Patients with renal dysfunction eGFR < 45 ml/min (according to the MDRD calculation)
- Patients with moderate or severe hepatic impairment (Child Pugh ≥ 7 points, i.e. class B or C)
- Patients with ongoing immunosuppression, systemic Cortisol treatment etc.
- Less than 3 months since previous ipsilateral venous intervention (e.g. Iliac recanalization)
- Clinically significant iliocaval stenosis or occlusion
- Current smoker of more than 20 cigarettes per day
- Other uncontrolled intercurrent illness that would jeopardize the patient's safety, interfere with the objectives of the protocol, or limit the patient's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor
- Patients with severe SARSCoV-2 virus infection requiring hospitalization in the past 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Personalized Tissue Engineered Vein
P-TEV
|
Replacement of vein with failing valves with personalized tissue engineering vein containing functional valves
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Thrombosis leading to occlusion of the graft measured by Color Duplex Ultrasound
Time Frame: 12 months
|
Ultrasonographic evaluation of occlusions of the graft.
|
12 months
|
Infection leading to surgical excision of the graft measured by blood samples
Time Frame: 12 months
|
White blood cells count: >10 x10E9/L, C- Reactive Protein (CRP): >4 mg/L, sedimentation rate: >12mm).
|
12 months
|
Infection leading to surgical excision of the graft measured by Color Duplex Ultrasound
Time Frame: 12 months
|
Ultrasonographic examination to assess infection of the graft
|
12 months
|
Infection leading to surgical excision of the graft measured by Computer Tomography
Time Frame: 12 months
|
Infection of the graft assessed by Computer Tomography
|
12 months
|
Reporting of surgical complications
Time Frame: 12 months
|
Perioperative surgical complications related to the implanted graft (technical failure leading to surgical failure).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in symptoms assessed according to VCSS (Venous Clinical Severity Score)
Time Frame: 12 months
|
The VCSS includes 9 hallmarks of venous disease, each scored on a severity scale from 0 (absent) to 3 (severe), plus a category for compression with higher scores representing greater compliance (still scale 0-3).
|
12 months
|
Change in symptoms assessed according to CEAP classification (clinical, etiologic, anatomic, pathophysiologic)
Time Frame: 12 months
|
CEAP classification is assessed on scale from C0 (No visible or palpable signs of venous disease) to C6 (Active venous ulcer).
|
12 months
|
Health Related Quality of Life assessed by VEINES questionnaire
Time Frame: 12 months
|
Responses are made on a 2- to 7-point scale that rates intensity, frequency, and agreement.
Higher scores are associated with better quality-of-life.The focus of VEINES is on physical symptoms as opposed to psychological or social aspects.
|
12 months
|
Durability of the P-TEV assessed by Color Duplex Ultrasound
Time Frame: 12 months
|
The time period in which the valve contained in the implant retains its function verified by ultrasonographic examination.
|
12 months
|
Vessel dilatation in the implant assessed by Duplex Color Ultrasound
Time Frame: 12 months
|
Ultrasonographic examination of vessel dilatation
|
12 months
|
Flow abnormalities in the implant assessed by Duplex Color Ultrasound
Time Frame: 12 months
|
Ultrasonographic examination of flow abnormalities
|
12 months
|
Wall degeneration in the implant assessed by Duplex Color Ultrasound
Time Frame: 12 months
|
Ultrasonographic examination of wall degeneration
|
12 months
|
Health Related Quality of Life assessed by EQ-5D-5L questionnaire
Time Frame: 12 months
|
EQ-5D-5L is a standardized self-assessment instrument for health status.It has two components; health state description and evaluation. The first part contains 5 items with five levels of response regarding five dimensions (mobility, hygiene, activities, pain and anxiety).The five questions are compounded into a health index according to a mathematical formula validated against the population in several countries.The second part of the questionnaire comprises a standard vertical 20-cm VAS that is calibrated from 'the worst health you can imagine' (scored 0) at its base to 'the best health you can imagine' (scored 100) at its apex. Respondents are asked to 'mark an X on the scale to indicate how your health is TODAY' and to write the number in an adjoining box. |
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Björquist, Verigraft AB
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015-004021-13
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Venous Insufficiency
-
Value Outcomes Ltd.Alfasigma S.p.A.RecruitingChronic Venous Disease | Chronic Insufficiency VenousCzechia
-
CEN BiotechTOWN HALL OF ROYATActive, not recruiting
-
State Budgetary Healthcare Institution, National...CompletedEndothelial Dysfunction | Venous Insufficiency of Leg | Venous Insufficiency (Chronic)(Peripheral)Russian Federation
-
Angiodynamics, Inc.Completed
-
Shannon HernonGalway ClinicUnknownChronic Venous InsufficiencyIreland
-
Virginia Commonwealth UniversityCompletedChronic Venous InsufficiencyUnited States
-
University of ZurichUnknown
-
TheraclionRecruitingChronic Venous InsufficiencyUnited States, Czechia, Austria
-
Technical University of LisbonFundação para a Ciência e a Tecnologia; Escola Superior de Saúde Dr. Lopes...CompletedChronic Venous InsufficiencyPortugal
-
InnoVeinRecruitingChronic Venous InsufficiencyAustralia
Clinical Trials on P-TEV
-
Teva Branded Pharmaceutical Products R&D, Inc.Terminated
-
Teva Branded Pharmaceutical Products R&D, Inc.RecruitingCrohn Disease | Colitis, UlcerativeUnited States, Hungary, Poland, Czechia, Japan, Belgium, Spain, Bulgaria, France, Italy, Slovakia, Austria
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedCluster HeadacheUnited States, Australia, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedAsthmaUnited States, Bulgaria, Czechia, Germany, Poland
-
Teva Branded Pharmaceutical Products R&D, Inc.WithdrawnType 2 Diabetes Mellitus | Nonalcoholic Steatohepatitis
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedChronic Cluster HeadacheUnited States, Australia, Canada, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedMigraineUnited States, Canada, Czechia, Finland, Israel, Japan, Poland, Russian Federation, Spain
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedPost-Traumatic HeadacheUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedEpisodic Cluster HeadacheUnited States, Australia, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom, Canada
-
Teva Branded Pharmaceutical Products R&D, Inc.RecruitingCrohn Disease | Colitis, UlcerativeUnited States, Bulgaria, Hungary, Poland, Spain, Belgium, Czechia, France, Italy, Japan, Norway, Slovakia, Germany, Canada, Ukraine, United Kingdom, Israel, Serbia